Skip to main content

Postdoctoral Research Scientist


Institute for Genomic Medicine (IGM) at Columbia University Irving Medical Center

Job Location

701 West 168 Street
New York, NY 10032
United States

Job Description

The Institute for Genomic Medicine (IGM) at Columbia University, in partnership with AstraZeneca’s Center for Genomics Research (CGR), is seeking a motivated and creative postdoctoral research scholar to uncover disease mechanisms across a wide range of conditions, and ultimately to drive the development of new precision medicines. The successful applicant will apply an existing gene-based rare-variant association pipeline as well as develop novel statistical genetics and computational methods to drive gene discovery from large whole exome and whole genome data sets, paired with corresponding phenotype data.

The successful candidate will be part of a vibrant research environment in the IGM. The IGM is an integral part of Columbia University’s Precision Medicine Initiative.  As part of this Initiative, the IGM sequences and performs comprehensive genomic analyses on more than 10,000 patient genomes per year in order to identify new therapeutic targets. The IGM utilizes mouse models and human pluripotent stem cells to understand how the implicated mutations contribute to disease phenotypes.

The successful candidate will also work with AstraZeneca’s CGR based in Cambridge UK, which implements the AstraZeneca Genomics Initiative. This Initiative aims to analyze data from up to 2 million genomes including genomic samples donated by patients in its clinical trials. This genome sequence data is linked to rich phenotypic records including data on disease and drug response data. This Initiative is expected to provide novel insights into the biology of disease, identify and validate new targets for medicines, improve selection of patients for clinical trials and match treatments to patients most likely to benefit.

This represents an exciting opportunity to be at the forefront of the rapidly expanding field of precision medicine and therapeutic discovery. In particular, these positions offer the opportunity of working within a prominent genomic medicine institute in close partnership with a leading pharmaceutical company, allowing candidates to participate in the full spectrum of precision medicine from target discovery and validation through to drug development.

Incumbents will be jointly supervised by several faculty in the Institute and will be employees of Columbia University and eligible for Columbia University programs and benefits while simultaneously benefitting from the IGM's alliance with AstraZeneca.

Essential qualifications/capabilities:

  • A Ph.D. or equivalent qualification in a quantitative field such as Genetics, Statistics/Biostatistics, Epidemiology, Bioinformatics, Computer Science or other relevant discipline
  • A strong quantitative research background, statistical and programming proficiency, strong genetic knowledge
  • A demonstrated interest in using genetics to understand complex disease, leading to the discovery of new medicines
  • Extensive experience in scientific programming languages, such as Python and R
  • Proven communications skills, including writing of manuscripts and oral presentations
  • High capability to work in high performing teams

Preferred qualifications:

  • Practical experience of working with large-scale genetic data sets and producing high quality publications




How to Apply

Career Blog headlines

The Pandemic and Women in STEM

The New York Times reports on how the COVID-19 pandemic may affect women in STEM.

Missing from the Top

A new report finds that women, especially women of color, are missing among the high-earners at research universities in the US, the Chronicle of Higher Education writes. 

Time Lost

Researcher-parents, especially mothers of small children, have lost research time during the COVID-19 pandemic, according to the Chronicle of Higher Education.

Time of Preprints

Inside Higher Ed reports that the preprint site medRxiv has taken off with the COVID-19 pandemic.